Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs
- PMID: 24824037
- PMCID: PMC4085181
- DOI: 10.1158/1940-6207.CAPR-14-0120
Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs
Abstract
Prostaglandin E2 (PGE2) promotes colorectal carcinogenesis. Overall, systemic PGE2 production can be assessed by measuring its major metabolite, PGE-M, in urine. We examined the potential role of PGE-M as a biomarker for colorectal adenoma risk and chemopreventive response to anti-inflammatory drugs. We conducted a prospective case-control study nested within the Nurses' Health Study. Among women who previously provided a urine sample, we identified 420 cases diagnosed with colorectal adenoma during follow-up and matched them to 420 endoscopy-negative controls. We measured urinary PGE-M using an LC/MS assay. Compared with women in the lowest quartile of urinary PGE-M, women in the highest quartile had a multivariate OR of 1.40 (95% confidence interval (CI), 0.92-2.14) for any adenoma; 0.91 (95% CI, 0.48-1.72) for low-risk adenoma (solitary adenoma <1 cm in greatest diameter with tubular/unspecified histology); and 1.66 (95% CI, 1.04-2.67) for high-risk adenoma (adenoma ≥1 cm in greatest diameter and/or tubulovillous, villous or high-grade dysplasia histology or multiple adenomas of any size or histology). Regular use of anti-inflammatory drugs (≥2 standard tablets of aspirin/NSAIDs per week) was associated with a significant reduction in adenoma risk (multivariate OR, 0.61; 95% CI, 0.43-0.87) in women with high baseline PGE-M (quartiles 2-4), but not low PGE-M (quartile 1).Urinary PGE-M is associated with an increased risk of high-risk adenoma. Anti-inflammatory drugs seem to reduce adenoma risk among women with high, but not low PGE-M. Urinary PGE-M may serve as a biomarker to define subsets of the population who may obtain differential chemopreventive benefit from anti-inflammatory drugs.
©2014 American Association for Cancer Research.
Conflict of interest statement
Figures
Comment in
-
Urinary PGE-M in colorectal cancer: predicting more than risk?Cancer Prev Res (Phila). 2014 Oct;7(10):969-72. doi: 10.1158/1940-6207.CAPR-14-0215. Epub 2014 Jul 28. Cancer Prev Res (Phila). 2014. PMID: 25070664 Free PMC article.
References
-
- Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69–83. - PubMed
-
- Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterology. 2012;47:97–106. - PubMed
-
- Markowitz SD. Aspirin and colon cancer –targeting prevention? N Engl J Med. 2007;356:2195–8. - PubMed
-
- Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gasteroenterology. 1994;107:1183–8. - PubMed
-
- Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01CA087969/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- P30 DK043351/DK/NIDDK NIH HHS/United States
- UM1CA167552/CA/NCI NIH HHS/United States
- R01 CA137178/CA/NCI NIH HHS/United States
- K24 DK098311/DK/NIDDK NIH HHS/United States
- P50CA127003/CA/NCI NIH HHS/United States
- P01 CA55075/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- P01 CA055075/CA/NCI NIH HHS/United States
- R01 CA151993/CA/NCI NIH HHS/United States
- R01CA151993/CA/NCI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical